Organogenesis Holdings Inc.
NASDAQ: ORGO0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Capital Market
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Gary S. Gillheeney
- Employees
- 869
- Headquarters
- Canton, United States
- IPO year
- 2017
- Market cap
- $314.0M
- Website
- https://organogenesis.com
Loading ORGO…
Loading profile data…Frequently asked questions about ORGO
What does Organogenesis Holdings Inc. (ORGO) do?
Organogenesis Holdings Inc. is a U.S.-based regenerative medicine firm that specializes in creating, producing, and marketing innovative therapies for advanced wound management, as well as surgical and sports medicine applications. Within its advanced wound care portfolio, Organogenesis offers several distinct products. These include Affinity an...
Where does ORGO trade?
Organogenesis Holdings Inc. (ORGO) trades on the NASDAQ Capital Market.
What sector is ORGO in?
Organogenesis Holdings Inc. (ORGO) operates in the Healthcare sector, specifically in the Drug Manufacturers - Specialty & Generic industry.
Who is the CEO of Organogenesis Holdings Inc.?
Gary S. Gillheeney is the chief executive officer of Organogenesis Holdings Inc. (ORGO).
Where is Organogenesis Holdings Inc. headquartered?
Organogenesis Holdings Inc. is headquartered in United States.
Does ORGO pay a dividend?
Organogenesis Holdings Inc. (ORGO) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did ORGO go public?
Organogenesis Holdings Inc. (ORGO) completed its initial public offering in 2017.